Financial Watchlist of Valeant Pharmaceuticals International, Inc. (NYSE:VRX)Quarterly Sales and EPS Roundup:
Valeant Pharmaceuticals International, Inc. (VRX) reported sales (ttm) of 9.67 Billion, whereas, 12 number of analysts estimated the mean sale of 2198.07 million. The analysts estimated sales for the higher end at 2281.6 million and lower end at 2080.5 million while the year ago reported sale was 0 million.
12 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 2148.28 million while high and low sale targets are estimated at 2258.3 million and 1990 million respectively.
Valeant Pharmaceuticals International, Inc. (VRX) reported earning per shares for the quarter ending Feb 28 BMO at 0.69, whereas, 15 number of analysts estimated the mean EPS at 0.95. The analysts estimated EPS for the higher end at 1.21 and lower end at 0.37 while the year ago reported earnings per share was 2.86.
The company has mean EPS estimate of 0.95 reported by 15 number of analyst for the quarter. The analysts estimated mean EPS at 0.95 while the high and low EPS estimate stand at 1.24 and 0.74 respectively. In contrast to the year ago quarter EPS was at 2.92. EPS long term mean growth rate estimated by 1 analysts is at 16.9%, whereas, the high and low Long term growth rate estimated at 16.9 and 16.9.
Valuation Ratios of Valeant Pharmaceuticals International, Inc. (VRX) versus the Industry and Sector:
Let’s have a look at some of the important valuation ratios of the Valeant Pharmaceuticals International, Inc. (VRX). These ratios are important while doing valuation of the company or the shares of the company.
Valeant Pharmaceuticals International, Inc. (VRX) currently has P/E (Price to Earnings) ratio of 0 while the company’s industry has 28.77 P/E and the sector P/E is 29.67. Similarly, the company’s last 5 years high P/E ratio is 55.49 and low P/E is 55.49, whereas, the industry’s and sector’s high P/E for the past year is 42.14 and 44.5 respectively and low P/E ratio for the last 5 years is 21.94 for the industry and 23.02 for the Sector.
Beta is also an important valuation ratio for analyzing the stock of the company, VRX has Beta of -0.09 while its industry and Sector’s beta remains at 0.83 and 0.82 respectively.
Price to Sale ratio of VRX stands at 0.32 while Price to Book Ratio stands at 1. Its Price to Cash Flow ratio shows the value of 6.71, whereas, the industry and sector ratio of Price to Cash Flow ticked at 22.44 and 22.87 respectively.
5 Year Growth Rate Analysis:
Growth rates are very important while analyzing the long term growth and valuation of a certain company.
5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Valeant Pharmaceuticals International, Inc. (VRX) stands at 31.85 while the industry’s and the sector’s growth for next 5 years ticked at 10.5 and 10.73 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 0 and -5.49.
Valeant Pharmaceuticals International, Inc. (VRX) Trading Statistics:
The company declined -1.55% and closed its last trading session at $9.02. The market capitalization of the company is at $3.03 Billion. The stock touched 52-week High of $38.50 on 05/03/16 and 52-week Low of $8.92 on 04/20/17. The stock currently has Weekly Volatility of 3.04% and Monthly Volatility of 3.62%. The Beta for the company stands at -0.1 and its Average True Range (ATR) shows a value of 0.41.